secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001743881-26-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q1 rev $194.5M, Attruby sales $180.6M; $500M share buyback authorized
-------------------------------------------------------------------------------

- Q1 2026 total revenues net $194.5M, up from $116.6M YoY; Attruby U.S. net product revenue $180.6M.
- Net loss attributable to common stockholders $164.0M ($0.84 per share), vs $167.4M ($0.88) in Q1 2025.
- Cash, equivalents & marketable securities $940.2M as of March 31, 2026, up from $587.5M at Dec 31.
- Board authorized $500M stock repurchase program; buybacks may occur open market or privately.
- Submitted NDA for BBP-418 (LGMD2I/R9) to FDA; encaleret NDA planned 1H 2026; infigratinib NDA Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/0001743881-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/bbio-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001743881-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer